Candel Therapeutics, Inc. CADL

CADL Company Overview

Candel Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing multimodal biological immunotherapies for the treatment of solid tumors. The company operates within the oncology and immunotherapy sectors, with a primary emphasis on genetically modified viral platforms designed to stimulate anti-tumor immune responses and improve long-term cancer control. Its core therapeutic approach combines viral immunotherapy with induction of systemic immune activation intended to generate both direct tumor cell killing and broader immune-mediated anti-cancer effects.

The company’s principal product candidates include adenovirus- and herpes simplex virus-based investigational therapies, most notably CAN-2409 and CAN-3110, which have been studied in cancers including prostate cancer, non-small cell lung cancer, pancreatic cancer, and recurrent high-grade glioma. Candel Therapeutics evolved from earlier viral gene therapy research programs and advanced into a publicly traded biotechnology company focused on clinical development and translational oncology research. Its strategic positioning is centered on leveraging viral vectors to potentially enhance immune recognition of tumors while integrating with existing standards of care such as radiation, surgery, and immune checkpoint inhibitors.